Jaguar Health, Inc. (NASDAQ:JAGX) Short Interest Up 138.4% in October

Jaguar Health, Inc. (NASDAQ:JAGX) was the recipient of a large increase in short interest in October. As of October 31st, there was short interest totalling 332,300 shares, an increase of 138.4% from the October 15th total of 139,400 shares. Based on an average daily volume of 312,000 shares, the days-to-cover ratio is currently 1.1 days. Currently, 4.3% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded Jaguar Health from a “sell” rating to a “hold” rating in a report on Friday, September 13th.

Jaguar Health Stock Down 3.8 %

JAGX traded down $0.04 during trading on Wednesday, hitting $1.05. The company had a trading volume of 451,171 shares, compared to its average volume of 746,564. Jaguar Health has a 1-year low of $0.90 and a 1-year high of $30.86. The company has a current ratio of 2.10, a quick ratio of 1.60 and a debt-to-equity ratio of 1.32. The business has a 50-day moving average of $1.15 and a 200-day moving average of $3.79.

Jaguar Health (NASDAQ:JAGX) last announced its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($4.04) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($2.84). Jaguar Health had a negative net margin of 350.18% and a negative return on equity of 412.63%. The firm had revenue of $2.72 million during the quarter. On average, equities analysts anticipate that Jaguar Health will post -0.78 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Jaguar Health stock. Perritt Capital Management Inc acquired a new position in shares of Jaguar Health, Inc. (NASDAQ:JAGX) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 25,000 shares of the biotechnology company’s stock, valued at approximately $90,000. Perritt Capital Management Inc owned about 0.51% of Jaguar Health at the end of the most recent reporting period. Institutional investors and hedge funds own 12.04% of the company’s stock.

About Jaguar Health

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.